Submit to JPM Review for JPM Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "Precision and Regenerative Medicine for Tissue Repair"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Regenerative Medicine and Therapeutics".

Deadline for manuscript submissions: closed (30 October 2023) | Viewed by 5921

Share This Special Issue

Special Issue Editor

Dr. Fei Xing

E-Mail Website
Guest Editor

Department of Orthopedics, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu 610041, China
Interests: 3D printing; stem cells; bone regeneration; bone fracture; biomaterials; tissue engineering; regenerative medicine; precision medicine

Special Issue Information

Dear Colleagues,

Recently, “precision medicine”, a type of medical treatment tailored to individual needs, has become very popular across medical disciplines. As a novel field of medicine, precision medicine is an innovative approach that considers individual differences in people's genes, environments, and lifestyles, offering a new medical model for the treatment of various diseases. Precision medicine emphasizes that disease-specific treatments should no longer be applied to all afflicted patients; instead, it posits that the treatment target of precision medicine should be individual, considering genetic and environmental variability, among other factors. The goal of regenerative medicine is to repair damaged tissues and restore normal tissue function. Precision and regenerative medicine intersect in multiple aspects, such as genomics, genetics, nanomedicine, and data science. In addition, combining precision medicine with regenerative medicine can achieve the personalized repair of damaged tissues and promote the development of new therapies. This Special Issue aims to bring together innovative and successful findings in precision and regenerative medicine for personalized tissue regeneration and discuss recent trends and strategies in this field.

Dr. Fei Xing
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

precision medicine
regenerative medicine
tissue engineering
tissue repair
personalized tissue regeneration
stem cells
genomics
genetics
nanomedicine

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1800 KiB

Open AccessArticle

Adipose-Derived Mesenchymal Stem Cell (MSC) Immortalization by Modulation of hTERT and TP53 Expression Levels

Aigul R. Rakhmatullina

and

J. Pers. Med. 2023, 13(11), 1621; https://doi.org/10.3390/jpm13111621 - 20 Nov 2023

Viewed by 369

Abstract

Mesenchymal stem cells (MSCs) are pivotal players in tissue repair and hold great promise as cell therapeutic agents for regenerative medicine. Additionally, they play a significant role in the development of various human diseases. Studies on MSC biology have encountered a limiting property of these cells, which includes a low number of passages and a decrease in differentiation potential during in vitro culture. Although common methods of immortalization through gene manipulations of cells are well established, the resulting MSCs vary in differentiation potential compared to primary cells and eventually undergo senescence. This study aimed to immortalize primary adipose-derived MSCs by overexpressing human telomerase reverse transcriptase (hTERT) gene combined with a knockdown of TP53. The research demonstrated that immortalized MSCs maintained a stable level of differentiation into osteogenic and chondrogenic lineages during 30 passages, while also exhibiting an increase in cell proliferation rate and differentiation potential towards the adipogenic lineage. Long-term culture of immortalized cells did not alter cell morphology and self-renewal potential. Consequently, a genetically stable line of immortalized adipose-derived MSCs (iMSCs) was established. Full article

(This article belongs to the Special Issue Precision and Regenerative Medicine for Tissue Repair)

► Show Figures

Figure 1

Review

Jump to: Research

40 pages, 11309 KiB

Open AccessReview

Progress in Research on Stem Cells in Neonatal Refractory Diseases

and

J. Pers. Med. 2023, 13(8), 1281; https://doi.org/10.3390/jpm13081281 - 21 Aug 2023

Viewed by 719

Abstract

With the development and progress of medical technology, the survival rate of premature and low-birth-weight infants has increased, as has the incidence of a variety of neonatal diseases, such as hypoxic–ischemic encephalopathy, intraventricular hemorrhage, bronchopulmonary dysplasia, necrotizing enterocolitis, and retinopathy of prematurity. These diseases cause severe health conditions with poor prognoses, and existing control methods are ineffective for such diseases. Stem cells are a special type of cells with self-renewal and differentiation potential, and their mechanisms mainly include anti-inflammatory and anti-apoptotic properties, reducing oxidative stress, and boosting regeneration. Their paracrine effects can affect the microenvironment in which they survive, thereby affecting the biological characteristics of other cells. Due to their unique abilities, stem cells have been used in treating various diseases. Therefore, stem cell therapy may open up the possibility of treating such neonatal diseases. This review summarizes the research progress on stem cells and exosomes derived from stem cells in neonatal refractory diseases to provide new insights for most researchers and clinicians regarding future treatments. In addition, the current challenges and perspectives in stem cell therapy are discussed. Full article

(This article belongs to the Special Issue Precision and Regenerative Medicine for Tissue Repair)

► Show Figures

Figure 1

13 pages, 1722 KiB

Open AccessReview

The Efficiency and Safety of Platelet-Rich Plasma Dressing in the Treatment of Chronic Wounds: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

and

J. Pers. Med. 2023, 13(3), 430; https://doi.org/10.3390/jpm13030430 - 27 Feb 2023

Cited by 2 | Viewed by 1083

Abstract

Recently, many clinical trials have applied platelet-rich plasma (PRP) dressings to treat wounds that have stopped healing, which are also called chronic wounds. However, the clinical efficiency of PRP dressings in treating chronic wounds is still controversial. Therefore, we conducted this study to compare PRP dressings with normal saline dressings in treating chronic wounds. Relevant randomized controlled trials focusing on utilizing PRP dressings in treating chronic wounds were extracted from bibliographic databases. Finally, 330 patients with chronic wounds, reported in eight randomized controlled trials, were included in this study. In total, 169 out of 330 (51.21%) were treated with PRP dressings, and 161 out of 330 (48.79%) were treated with normal saline dressings. The pooled results showed that the complete healing rate of the PRP group was significantly higher than that of saline group at 8 weeks and 12 weeks, respectively. In addition, there were no significant differences in wound infection and adverse events. Compared with normal saline dressing, the PRP dressing could effectively enhance the prognosis of chronic wounds. Furthermore, the PRP did not increase wound infection rate or occurrence of adverse events as an available treatment for chronic wounds. Full article

(This article belongs to the Special Issue Precision and Regenerative Medicine for Tissue Repair)

► Show Figures

Graphical abstract

16 pages, 5349 KiB

Open AccessReview

Multiple Injections of Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Current Evidence in Randomized Controlled Trials

and

J. Pers. Med. 2023, 13(3), 429; https://doi.org/10.3390/jpm13030429 - 27 Feb 2023

Viewed by 3058

Abstract

In recent years, various clinical trials have focused on treating knee osteoarthritis (KOA) with multiple injections of platelet-rich plasma (PRP). However, compared with the multiple hyaluronic acid (m-HA) injections, the clinical efficacy of multiple PRP (m-PRP) injections for KOA still remains controversial among these studies. Therefore, we aimed to compare the clinical effectiveness of m-PRP injections with m-HA injections in the treatment of KOA in this systematic review. Relevant clinical trials were searched via bibliographic databases, including Medline, PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials, to compare the m-PRP and m-HA injections in the treatment of KOA. Finally, fourteen randomized controlled trials, including 1512 patients, showed the postoperative VAS, WOMAC, IKDC, or EQ-VAS scores and were enrolled in this systematic review. Compared with the group of intra-articular m-HA injections, the group of intra-articular m-PRP injections was lower in the VAS scores at 3-month (WMD = −0.25; 95%CI, −0.40 to −0.10, p = 0.0009) and 12-month (WMD = −0.64; 95%CI, −0.79 to −0.49, p < 0.00001) follow-ups. In addition, the group of intra-articular m-PRP injections was also lower in the WOMAC scores at 1-month (WMD = −1.23; 95%CI, −2.17 to −0.29, p = 0.01), 3-month (WMD = −5.34; 95%CI, −10.41 to −0.27, p = 0.04), 6-month (WMD = −11.02; 95%CI, −18.09 to −3.95, p = 0.002), and 12-month (WMD = −7.69; 95%CI, −12.86 to −2.52, p = 0.004) follow-ups. Furthermore, compared with the group of intra-articular m-HA injections, the group of intra-articular m-PRP injections was higher in the IKDC scores at 3-month (WMD = 7.45; 95%CI, 2.50 to 12.40, p = 0.003) and 6-month (WMD = 5.06; 95%CI, 1.94 to 8.18, p = 0.001) follow-ups. However, the long-term adverse side of m-PRP injections for KOA still needs more large-scale trials and long-term follow-ups. Full article

(This article belongs to the Special Issue Precision and Regenerative Medicine for Tissue Repair)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Precision and Regenerative Medicine for Tissue Repair"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (4 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI